EPIGRAL Epigral Q4 FY25 results (Jan–Mar 2025) and concall
Epigral Limited delivered a strong Q4 and FY25 performance, achieving record revenue and PAT, primarily fueled by the growth in its Derivatives & Specialty segment. The company successfully commissioned new capacities and significantly deleveraged its balance sheet. While facing some pricing headwinds in hydrogen peroxide and CPVC, management remains optimistic about future volume growth and margin sustainability through diversification and operational efficiencies.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 |
|---|---|---|---|
| Revenue | 626 | 645 | 628 |
| EBITDA | 178 | 183 | 173 |
| Net profit | 81 | 104 | 87 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
